Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali

被引:26
作者
Boileau, Catherine [1 ]
Nguyen, Vinh-Kim [2 ]
Sylla, Mohamed [3 ]
Machouf, Nima [4 ]
Chamberland, Annie [3 ]
Traore, Hamar A. [5 ]
Niamba, Pascal A. [6 ]
Diallo, Ismael [7 ]
Maiga, Moussa [8 ]
Cisse, Mamadou [9 ]
Rashed, Selim [10 ]
Tremblay, Cecile [3 ]
机构
[1] McGill Univ, Inst Hlth & Social Policy, Montreal, PQ H3A 1A3, Canada
[2] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada
[3] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[4] Clin Med Lactuel, Montreal, PQ, Canada
[5] Hop Natl Point G, Unite Med Interne, Bamako, Mali
[6] Ctr Univ Hosp Yalgado Ouedraogo, Unite Dermatol, Ouagadougou, Burkina Faso
[7] Ctr Univ Hosp Yalgado Ouedraogo, United Med Interne, Ouagadougou, Burkina Faso
[8] Hop Gabriel Toure, Bamako, Mali
[9] VIH SIDA CESAC, Ctr Soins Animat & Conseils Personnes Atteintes, Bamako, Mali
[10] Univ Montreal, Unite Sante Int, Montreal, PQ, Canada
关键词
viral load; antiretroviral treatment monitoring; sub-Saharan Africa; immune suppression; public hospital; community-based organization;
D O I
10.1097/QAI.0b013e31817dc416
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Sub-Saharan Africa has seen dramatic increases in the numbers of people treated with antiretroviral therapy (ART). Although standard ART regimens are now universally applied, viral load measurement is not currently part of standard monitoring protocols in sub-Saharan Africa. Methods: We describe the prevalence of inadequate virological response (IVR) to ART (viral load >= 500 copies/mL) and identify factors associated with this outcome in 606 HIV-positive patients treated for at least 6 months. Recruitment took place in 7 hospitals and community-based sites in Bamako and Ouagadougou, and information was collected using medical charts and interviews. Results: The overall prevalence of IVR in treatment-naive patients was 12.3% and 24.4% for pretreated patients. There were no differences in rates of IVR according to ART delivery sites and time on treatment. Patients living farther away [odds ratio (OR) = 2.48; 95% confidence interval (CI) 1.40 to 4.39], those on protease inhibitor or nucleoside reverse transcriptase inhibitor regimens (OR = 3.23; 95% CI 1.79 to 5.82) and those reporting treatment interruptions (OR = 2.36; 95% CI 1.35 to 4.15), had increased odds of IVR. Immune suppression (OR = 3.32, 95% CI 1.94 to 5.70) and poor self-rated health (OR = 2.00; 95% CI 1.17 to 3.41) were also associated with IVR. Conclusions: Sufficient expertise and dedication exist in public hospital and community-based programs to achieve rates of treatment success comparable to beter-resourced settings.
引用
收藏
页码:476 / 484
页数:9
相关论文
共 45 条
[1]   Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy [J].
Abgrall, S ;
Duval, X ;
Joly, V ;
Descamps, D ;
Matheron, S ;
Costagliola, D .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (11) :1517-1526
[2]  
Anastos K, 2000, J ACQ IMMUN DEF SYND, V24, P218
[3]  
[Anonymous], 2006, Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach 2006 revision, P1, DOI DOI 10.1016/0004-6981(88)90109-6
[4]   Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].
Bartlett, JA ;
DeMasi, R ;
Quinn, J ;
Moxham, C ;
Rousseau, F .
AIDS, 2001, 15 (11) :1369-1377
[5]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[6]  
Boyd MA, 2006, ANTIVIR THER, V11, P223
[7]  
Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
[8]   Adherence to HIV antiretroviral therapy in HIV plus Ugandan patients purchasing therapy [J].
Byakika-Tusiime, J ;
Oyugi, JH ;
Tumwikirize, WA ;
Katabira, ET ;
Mugyenyi, PN ;
Bangsberg, DR .
INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (01) :38-41
[9]   Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa [J].
Coetzee, D ;
Hildebrand, K ;
Boulle, A ;
Maartens, G ;
Louis, F ;
Labatala, V ;
Reuter, H ;
Ntwana, N ;
Goemaere, E .
AIDS, 2004, 18 (06) :887-895
[10]   Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire [J].
Djomand, G ;
Roels, T ;
Ellerbrock, T ;
Hanson, D ;
Diomande, F ;
Monga, B ;
Maurice, C ;
Nkengasong, J ;
Konan-Koko, R ;
Kadio, A ;
Wiktor, S ;
Lackritz, E ;
Saba, J ;
Chorba, T .
AIDS, 2003, 17 :S5-S15